Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis | Scientific Reports
SGLT2 Inhibitors in Type 1 Diabetes: Friend or Foe? - Taking Control Of Your Diabetes®
Cureus | Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?
EMA hält SGLT2-Inhibitor auch bei Typ-1-Diabetes für geeignet
SGLT2-Inhibitoren: Was gibt es Neues? | SpringerLink
Typ-1-Diabetes
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes | NEJM
FDA says no to Lilly, Boehringer's Jardiance in type 1 diabetes - PMLiVE
JCM | Free Full-Text | SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes | PLOS ONE
FDA weighs risks of new treatment for type 1 diabetes - Diabetes Voice
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes | PLOS ONE
Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta‑analysis of randomized controlled trials
Hypothesized renal hemodynamic effects of sodium-glucose... | Download Scientific Diagram
![Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY](https://www.touchendocrinology.com/wp-content/uploads/sites/5/2017/11/figure1-potential-mechanisms-for-sodium-glucose.png "Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY")
Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY
Zusätzlich zu Insulin – SGLT2-Hemmer erhält Zulassung für Typ-1-Diabetes
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus - The Lancet Diabetes & Endocrinology
![Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY](https://www.touchendocrinology.com/wp-content/uploads/sites/5/2017/11/table1-minimizing-the-risk-of-diabetic.png "Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY")
Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY
Insulin Therapy in Combination With SGLT2 Inhibitors in Type 1 and Type... | Download Table
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes? | Arteriosclerosis, Thrombosis, and Vascular Biology
Could SGLT2 Inhibitors Be Part of a New Treatment for Type 1 Diabetes? – BETTER
Typ-1-Diabetes
SGLT inhibitors for type 1 diabetes: a finely balanced matter?
2 Medikamentöse Therapie des Glukosestoffwechsels — Leitlinien.de
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus | Circulation
